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Survival of patients with chronic myeloproliferative 
neoplasms and new primary cancers: a population-based 
cohort study
Henrik Frederiksen, Dóra Körmendiné Farkas, Christian Fynbo Christiansen, Thomas Stauﬀ er Larsen, Hans Carl Hasselbalch, Jesper Stentoft, 
Henrik Toft Sørensen
Summary
Background Patients with chronic myeloproliferative neoplasms are at increased risk of new solid or haematological 
cancers, but how prognosis is aﬀ ected in patients with preceding myeloproliferative neoplasms is unclear.
Methods We used data from population-based medical databases in Denmark from 1980 to 2011 to compare survival 
between cancer patients with and without a preceding diagnosis of myeloproliferative neoplasm, matched for age, 
sex, year of diagnosis, and type of cancer. We assessed outcomes by cancer stage and comorbidities. 
Findings Data were available for 1246 patients with a history of myeloproliferative neoplasms and we matched 5155 patients 
without a history of myeloproliferative neoplasm for comparison. Among patients with new localised solid cancers, 
5-year survival was 49·8% (95% CI 39·1–59·6) for patients with preceding essential thrombocythaemia, 47·9% 
(42·1–53·4) for those with preceding polycythaemia vera, and 48·0% (34·1–60·7) for those with preceding chronic 
myeloid leukaemia. The values were 72·4% (68·4–76·0), 63·9% (61·5–66·2), and 74·3% (68·2–79·4), respectively, in 
matched patients without preceding myeloproliferative neoplasms. The risk of death among patients with a solid 
tumour and preceding myeloproliferative neoplasm was 1·21–2·28 times higher than in patients without 
myeloproliferative neoplasms. Excess mortality risk was observed irrespective of whether new cancers were diagnosed 
within 5 years or 5 years or more after myeloproliferative neoplasm.
Interpretation Preceding myeloproliferative neoplasm is a predictor for poor outlook in patients who develop new 
primary cancers.
Funding Lundbeck and Novo Nordisk Foundation Programme for Clinical Research Infrastructure, Danish Cancer 
Society, and Aarhus University Research Foundation.
Introduction
Classic chronic myeloproliferative neoplasms encompass 
essential thrombocythaemia, polycythaemia vera, 
myeloﬁ brosis, and chronic myeloid leukaemia.1 These 
neoplasms have an inherent tendency to evolve into 
myeloid cancers, such as acute myeloid leukaemia, and 
the risk of lymphoid haematological neoplasms is higher 
than that in the general population.2–4 Although adequate 
management can result in a long life expectancy,5–8 the 
prognosis for patients in whom myeloproliferative 
neoplasms transform into acute leukaemia is poor, with 
median survival being 2–5 months.9–11
We found that among 7229 patients with 
myeloproliferative neoplasms, risk of new solid cancers 
was 40% higher than that in the general population.12 The 
new cancers developed within a median of 4 years of 
follow-up. The reasons for this increased risk remain 
unknown, although underlying vulnerability to cancer, the 
myeloproliferative neoplasm itself, and treatment have 
been suggested.13–17 The latter hypothesis was supported in 
a study of 1445 patients with chronic myeloid leukaemia or 
other myeloproliferative neoplasms treated with tyrosine-
kinase inhibitors (TKIs), where there were 40% fewer 
second cancers when compared with the number expected 
from the Surveillance, Epidemiology, and End Results 
database during the 8·9 years of follow-up.18
We did a population-based registry study to investigate 
how the outlook of patients who develop new primary 
solid or haematological cancers is aﬀ ected by a preceding 
diagnosis of myeloproliferative neoplasm.
Methods
Registries
We identiﬁ ed all patients in three Danish national 
databases, the Danish National Patient Registry (DNPR), 
Danish Cancer Registry (DCR), and Danish Civil 
Registration System (CRS),19–22 who had received a 
diagnosis of myeloproliferative neoplasm from 1980 to 
2011. Since 1968, all residents of Denmark have received 
a unique civil registration number from the CRS, which 
allows unambiguous individual-level linkage across all 
Danish registries.21 The CRS records the date of birth, 
sex, date of emigration, and vital status of all Danish 
residents and is continuously updated.21
The DNPR contains information on all discharges 
from Danish public hospitals since 1977 and on 
outpatient specialist clinic visits since 1995.20 Denmark 
has very few private hospitals, and none is engaged in 
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cancer management. Data recorded in the DNPR include 
civil registration number, dates of outpatient clinic visits, 
dates of hospital admission and discharge, and up to 
20 diagnoses coded by physicians according to the 
International Classiﬁ cation of Diseases, eighth revision 
(ICD-8) in 1977–93 and tenth revision (ICD-10) thereafter. 
Diagnostic coding of haematological malignancies in the 
DNPR has been validated.23 We selected all cases of 
myeloproliferative neoplasms according to the ICD-8 
and ICD-10 codes (appendix). Because there is no speciﬁ c 
diagnosis code for primary myeloﬁ brosis in ICD-10, we 
separated patients into three groups based on the 
available diagnosis codes for essential thrombocythaemia, 
polycythaemia vera, and chronic myeloid leukaemia.
We took the ﬁ rst hospital admission or visit to an 
outpatient clinic associated with a diagnosis of 
myeloproliferative neoplasm to be the date of diagnosis. 
We identiﬁ ed diagnoses of new primary cancers through 
linkage to the DCR, which has recorded all cancer 
diagnoses since 194319,22 and uses the ICD-10 classiﬁ cation 
system. Clinical stage at time of diagnosis is classiﬁ ed in 
the DCR as localised, regional spread, distant metastatic 
spread, or unknown.19,22 The DCR has been found to be 
95–98% complete and valid.22
Patients
The inclusion criteria have been described previously.12 
Eligible patients were aged 20 years or older at the time 
of diagnosis of myeloproliferative neoplasm and 
developed a new primary cancer afterwards. We excluded 
patients with myeloproliferative neoplasms that were 
preceded by a diagnosis of another cancer, except for 
non-melanoma skin cancer or carcinoma in situ of the 
cervix uteri. Patients with a diagnosis of a new primary 
solid or haematological cancer within 1 year after 
diagnosis of myeloproliferative neoplasm were deemed 
to have concurrent cancers and were also excluded.
For each patient with a history of myeloproliferative 
neoplasm and a second cancer, we identiﬁ ed ﬁ ve patients 
in the databases matched for new primary cancer type 
but with no preceding myeloproliferative neoplasm. The 
patients in the comparison cohort were also matched for 
sex, age (in 1-year age groups), and time of cancer 
diagnosis, within the following time periods: 1980–84, 
1985–89, 2000–04, 2005–09, and 2010–11. For 90 patients 
with myeloproliferative neoplasms (24 with essential 
thrombocythaemia, 57 with polycythaemia vera, and nine 
with chronic myeloid leukaemia) fewer than ﬁ ve 
matching patients could be identiﬁ ed.
Ethics approval for this study was provided by the 
Danish Data Protection Agency. 
Comorbidity
We used the Charlson Comorbidity Index (CCI) to assess 
eﬀ ects of comorbidities on survival.24 The CCI is a 
weighted index that summarises the number and 
seriousness of 19 chronic disorders. Four of these are 
cancers, which we excluded. Information on the 
remaining CCI disorders was obtained through retrieval 
of diagnoses from the DNPR recorded within the 5 years 
before the diagnosis of the new primary cancer.25 CCI 
scores were grouped into three categories: low 
comorbidity (score of 0); moderate comorbidity (1–2); 
and severe comorbidity (a score of 3 or higher).
Statistical analysis
For all patients, follow-up began on the date of the ﬁ rst 
hospital admission or ﬁ rst visit to an outpatient specialist 
clinic associated with the diagnosis of the new primary 
solid or haematological cancer. Follow-up continued 
until death, emigration, or Jan 1, 2013, whichever 
occurred ﬁ rst. Analyses were done separately for solid 
and haematological cancers. Patients with myelo-
proliferative neoplasms who received another diagnosis 
of myeloproliferative neoplasm or chronic myeloid 
leukaemia during follow-up were not deemed to have a 
new cancer.
We used the prevalence proportion ratio (PPR) to 
compare extent of cancer spread and CCI scores of the 
new primary cancer at diagnosis among patients with 
and without preceding myeloproliferative neoplasms. 
PPRs and 95% CIs were calculated by dividing the 
proportion of cancer patients with the greatest spread or 
highest CCI score and preceding myeloproliferative 
neoplasms by the proportion of cancer patients with the 
greatest spread or highest CCI score but no preceding 
myeloproliferative neoplasms. We also used PPR 
calculations to compare diﬀ erences between subgroups 
of cancer spread (localised, regional, or unknown) and 
severity of comorbidity.
The cumulative incidence of cancer during the ﬁ rst 
5 years after the diagnosis of myeloproliferative neoplasm 
was computed with 95% CIs, with death taken to be a 
competing risk. The values were compared with those in 
the similar age group of the general population in 
Denmark.26 We used the Kaplan-Meier method to 
construct survival curves after the diagnosis of a new 
primary cancer and to compare mortality across 
categories of cancer spread and comorbidity. We used 
Cox’s proportional hazards regression analysis to 
compare death rates between cancer patients with and 
without preceding myeloproliferative neoplasms. We 
calculated hazard ratios (HRs) and 95% CIs for 
myeloproliferative neoplasm exposure (essential 
thrombocythaemia, polycythaemia vera, or chronic 
myeloid leukaemia), adjusted for age, CCI score, and 
cancer stage (solid cancers only). HRs were computed 
separately for cancers that occurred within 5 years or 
5 years or more after the diagnosis of myeloproliferative 
neoplasm. Since patients diagnosed as having myelo-
proliferative neoplasms in outpatient clinics could be 
included only from 1995, we stratiﬁ ed analyses by the 
time periods 1980–94 and 1995–2011. In 2000, TKIs 
began to be used to treat chronic myeloid leukaemia in 
See Online for appendix
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Denmark. To assess the possible eﬀ ect of this new 
treatment on the outlook of patients with chronic myeloid 
leukaemia and a subsequent cancer, we stratiﬁ ed 
analyses by the time periods 1980–99 and 2000–11.
As we had no information on smoking status, we used 
diagnosis of chronic obstructive pulmonary disease 
(COPD) as a proxy measure (appendix). Because blood 
test results for heavy smokers might resemble those of 
myelo proliferative neoplasms, diagnostic misclassi-
ﬁ cation could occur. To assess the potential eﬀ ect of 
diagnostic misclassiﬁ cation of myeloproliferative 
neoplasm on survival, we stratiﬁ ed analyses according to 
whether a diagnosis of COPD had been made before or 
at the time of the diagnosis of myeloproliferative 
neoplasm.27 The assumption of proportional hazards was 
assessed graphically in all models and found to be 
appropriate.
Information on causes of death was retrieved from the 
Danish Register of Causes of Death.28 The immediate 
causes of death, which were derived from death 
certiﬁ cates, were separated into six categories, according 
to ICD-8 codes from 1970–94 and ICD-10 codes thereafter: 
cardiovascular disease and thrombotic events, 
haematological cancers, all other cancers, infection, 
haemorrhagic episodes, and others.29 The analyses were 
done with SAS version 9.2. 
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data and had ﬁ nal responsibility for the 
decision to submit for publication. 
Results
From 1980 to 2011, we identiﬁ ed 2141 patients with 
essential thrombocythaemia, 4561 with polycythaemia 
vera, and 1164 with chronic myeloid leukaemia who had 
no previous or current cancer diagnosed other than 
myeloproliferative neoplasm, and who were alive 1 year 
after diagnosis. Of these, 302 patients with essential 
thrombocythaemia, 834 patients with polycythaemia 
vera, and 110 patients with chronic myeloid leukaemia 
subsequently developed a new primary cancer and were 
included in this study (table 1). Median follow-up for 
those who developed new solid cancers was 2·0 years 
(IQR 0·8–4·0) for patients with essential thrombo-
cythaemia, 1·9 years (0·4–4·3) for patients with 
polycythaemia vera, and 2·2 years (0·7–5·4) for patients 
with chronic myeloid leukaemia, and for those who 
developed new haematological cancers, was 0·7 years 
(IQR 0·2–1·8), 0·6 years (0·1–1·5), and 0·1 years 
(0·0–0·3), respectively.
The distribution of solid tumours was largely as 
expected26 except for non-melanoma skin cancer, which 
was more frequent in patients with previous myelo-
proliferative neoplasms. Distribution of speciﬁ c cancer 
types was similar in patients with essential thrombo-
cythaemia and polycythaemia vera, although breast 
cancer was more frequent in patients with essential 
thrombo cythaemia and lung cancer was more frequent 
in those with polycythaemia vera (table 1). The small 
number of chronic myeloid leukaemia cases precluded 
comparison of these patients with those who had other 
subtypes of myelo proliferative neoplasms. After the 
diagnosis of a new primary cancer, 6–14% of the patients 
were later diagnosed as having a second and up to 1% a 
third cancer, with no clear diﬀ erences in frequency 
between patients with preceding myeloproliferative 
neoplasms and those without.
At the time of diagnosis of new solid cancers in patients 
with preceding myeloproliferative neoplasms, the 
median age was 73·6 years (IQR 66·2–81·0) for those 
with essential thrombocythaemia, 72·1 years (65·3–78·6) 
Essential 
thrombocythaemia 
(n=302)
Polycythaemia vera 
(n=834)
Chronic myeloid 
leukaemia 
(n=110)
Solid cancers
Oropharynx 6 (2%) 12 (2%) 7 (7%)
Oesophagus 2 (1%) 13 (2%) 0
Stomach 1 (<1%) 14 (2%) 1 (1%)
Colon 9 (4%) 38 (5%) 4 (1%)
Rectum 7 (3%) 18 (3%) 3 (3%)
Liver, primary 1 (<1%) 9 (1%) 0
Pancreas 7 (3%) 15 (2%) 0
Larynx 2 (1%) 7 (1%) 0
Lung, primary 24 (10%) 113 (16%) 10 (11%)
Breast 29 (12%) 48 (7%) 5 (5%)
Cervix uteri 2 (1%) 6 (1%) 0
Corpus uteri 4 (2%) 14 (2%) 1 (1%)
Ovary 5 (2%) 2 (<1%) 1 (1%)
Prostate 20 (8%) 65 (9%) 8 (8%)
Kidney 4 (2%) 14 (2%) 0
Urinary tract 15 (6%) 44 (6%) 5 (5%)
Malignant melanoma 8 (3%) 20 (3%) 3 (3%)
Non-melanoma skin cancer 79 (32%) 183 (26%) 29 (31%)
Brain 6 (2%) 9 (1%) 3 (3%)
Other location* 14 (6%) 32 (5%) 13 (14%)
Carcinoma unspeciﬁ ed 5 (2%) 32 (5%) 2 (2%)
All non-haematological cancers 250 (100%) 708 (100%) 95 (100%)
Haematological cancers
Non-Hodgkin lymphoma 6 (12%) 20 (16%) 4 (27%)
Multiple myeloma 4 (8%) 10 (8%) 2 (13%)
Myelodysplastic syndrome 8 (15%) 11 (9%) 3 (20%)
Myeloid leukaemia 25 (48%) 59 (47%) 3 (20%)
Other leukaemia 8 (15%) 22 (18%) 1 (7%)
Haematological cancer unspeciﬁ ed* 1 (2%) 4 (3%) 2 (13%)
All haematological cancers 52 (100%) 126 (100%) 15 (100%)
Data are number (%). *Cancer types with fewer than ﬁ ve cases reported per site in all three chronic myeloproliferative 
neoplasm groups.
Table 1: Types of new primary cancers, by type of preceding myeloproliferative neoplasm 
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for those with polycythaemia vera, and 63·7 years 
(55·5–72·9) for those with chronic myeloid leukaemia. 
For patients with new haematological cancers, the 
median ages at the time of diagnosis were 70·4 years 
(64·1–75·9), 72·1 years (65·0–78·1), and 75·4 years 
(65·2–81·7), respectively. The cumulative incidence of 
solid cancer in the ﬁ rst 5 years after diagnosis for 
essential thrombocythaemia, polycythaemia vera, and 
chronic myeloid leukaemia was, respectively, 7·8% 
(95% CI 6·6–9·1), 6·8% (6·1–7·6), and 4·7% (3·5–6·1). 
The cumulative incidence of new haematological cancer 
was, respectively, 1·6% (1·1–2·3%), 1·2% (0·9–1·5), and 
1·0% (0·5–1·8).
From our database, we were able to match 
5155 patients with solid tumours or haematological 
malignancies without previous myeloproliferative 
neoplasm. Data on the extent of spread of solid cancers 
were available for 82–92% of patients and were similar 
in patients with and without preceding myelo-
proliferative neoplasms (table 2). Patients with 
preceding myelo proliferative neoplasms had more 
comorbidities than those without preceding myelo-
proliferative neoplasms (table 2). For patients who 
developed new haematological cancers, the prevalence 
of comorbidities was generally similar in patients with 
and without preceding myeloproliferative neoplasms 
(table 3). Owing to the small numbers of patients in the 
diﬀ erent categories, however, the estimated prevalence 
ratios were imprecise.
5-year survival after diagnosis of a new solid cancer, 
stratiﬁ ed by myeloproliferative neoplasm subtype, was 
consistently reduced over time in patients who had 
localised cancers or low comorbidity scores and 
preceding myeloproliferative neoplasms (ﬁ gures 1, 2). 
Among patients with preceding myeloproliferative 
neoplasms and with new localised cancers, 5-year 
survival was 49·8% (95% CI 39·1–59·6) for patients with 
essential thrombocythaemia, 47·9% (42·1–53·4) for 
those with polycythaemia vera, and 48·0% (34·1–60·7) 
for those with chronic myeloid leukaemia. In patients 
with localised cancers but no preceding myelo-
proliferative neoplasms, 5-year survival was 72·4% 
(68·4–76·0), 63·9% (61·5–66·2), and 74·3% (68·2–79·4), 
respectively. Similarly, among patients with myelo-
proliferative neoplasms but no comorbidities, 5-year 
survival was 50·7% (95% CI 40·1–60·4) for those with 
essential thrombocythaemia, 38·8% (33·3–44·2) for 
those with polycythaemia vera, and 48·3% (35·6–59·9) 
for those with chronic myeloid leukaemia. In comparison, 
among patients without preceding myelo proliferative 
neoplasms and no comorbidities, 5-year survival was 
60·3% (56·6–63·8), 48·2% (46·1–50·2), and 61·0% 
(55·5–66·0), respectively. The combined eﬀ ect of 
comorbidity and extent of cancer spread on survival is 
shown in the appendix. Among patients with metastasis 
or high comorbidity scores at the time of diagnosis of 
new cancers, survival was similar in those with and 
without myeloproliferative neoplasms (ﬁ gures 1 and 2).
Preceding ET 
(n=250)
No preceding ET 
(n=1234)
Prevalence ratio* 
(95% CI)
Preceding PV 
(n=708)
No preceding 
PV (n=3464)
Prevalence ratio* 
(95% CI)
Preceding CML 
(n=95)
No preceding CML 
(n=457)
Prevalence ratio* 
(95% CI)
CCI†
0 140 (56%) 938 (76%) 0·74 (0·66–0·83) 354 (50%) 2598 (75%) 0·67 (0·62–0·72) 69 (73%) 368 (81%) 0·90 (0·79–1·03)
1–2 96 (38%) 250 (20%) 1·90 (1·56–2·30) 295 (42%) 751 (22%) 1·92 (1·73–2·14) 24 (25%) 77 (17%) 1·50 (1·00–2·24)
≥3 14 (6%) 46 (4%) 1·50 (0·84–2·69) 59 (8%) 115 (3%) 2·51 (1·85–3·40) 2 (2%) 12 (3%) 0·80 (0·18–3·52)
Extent of spread‡
All 210 (84%) 1006 (82%) ·· 592 (84%) 2918 (84%) ·· 87 (92%) 393 (86%) ··
Localised 147 (70%) 698 (69%) 1·00 (0·92–1·11) 366 (62%) 1805 (62%) 1·00 (0·93–1·07) 61 (70%) 271 (69%) 1·01 (0·87–1·18)
Regional spread 34 (16%) 155 (15%) 1·05 (0·75–1·48) 101 (17%) 498 (17%) 1·00 (0·82–1·21) 11 (13%) 63 (16%) 0·79 (0·43–1·43)
Distant metastasis 29 (14%) 153 (15%) 0·91 (0·63–1·31) 125 (21%) 615 (21%) 1·00 (0·84–1·19) 15 (17%) 59 (15%) 1·14 (0·68–1·93)
Patients with and without preceding myeloproliferative neoplasms were matched for age, sex, year of cancer diagnosis, and cancer site. ET=essential thrombocythaemia. PV=polycythaemia vera. CML=chronic 
myeloid leukaemia. CCI=Charlson Comorbidity Index score. *Calculated as the ratio of the proportions of patients in the two groups with respect to the denoted category. †Excludes cancers. ‡Percentages 
restricted to patients with available data.
Table 2: Prevalence of comorbidity and extent of cancer spread among patients with a solid cancer 
Preceding ET 
(n=52)
No preceding ET 
(n=205)
Prevalence ratio† 
(95% CI)
Preceding PV 
(n=126)
No preceding PV 
(n=529)
Prevalence ratio† 
(95% CI)
Preceding CML 
(n=15)
No preceding 
CML (n=71)
Prevalence ratio† 
(95% CI)
CCI 0 36 (69%) 153 (75%) 0·93 (0·76–1·11) 79 (63%) 396 (75%) 0·84 (0·73–0·97) 8 (53%) 46 (65%) 0·82 (0·50–1·36)
CCI 1–2 12 (23%) 44 (22%) 1·08 (0·61–1·88) 41 (33%) 107 (20%) 1·61 (1·19–2·18) 6 (40%) 21 (30%) 1·35 (0·66–2·77)
CCI ≥3 4 (8%) 8 (4%) 1·97 (0·62–6·29) 6 (5%) 26 (5%) 0·97 (0·41–2·30) 1 (7%) 4 (6%) 1·18 (0·14–9·85)
Patients with and without preceding myeloproliferative neoplasms were matched for age, sex, year of cancer diagnosis, and cancer type. ET=essential thrombocythaemia. PV=polycythaemia vera. CML=chronic 
myeloid leukaemia. CCI=Charlson Comorbidity Index score. *Excludes cancers. †Calculated as the ratio of the proportions of patients in the two groups with respect to the denoted category.
Table 3: Prevalence of comorbidity* among patients with new haematological cancers 
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The risk of death was increased in patients with and 
without myeloproliferative neoplasms who developed 
new solid cancers (table 4). Increased risk remained 
irrespective of whether the new cancer was diagnosed 
within 5 years or 5 years or more after the diagnosis of 
myeloproliferative neoplasm. The mortality risk was 
substantially increased in patients with preceding 
myeloproliferative neoplasms and distant metastases or 
high comorbidity scores at the time of diagnosis of a 
new solid cancer (table 4). For patients with a 
haematological cancer, preceding myeloproliferative 
neoplasms were associated with a poorer outlook than 
no preceding neoplasm, but the HRs were imprecise 
(table 4).
We found no diﬀ erence in survival between 1980–94 
and 1995–2011 by preceding diagnosis of myelo-
proliferative neoplasm, cancer stage, or comorbidity in 
the analysis of change in myeloproliferative neoplasm 
case ascertainment strategy (data not shown). In the 
assessment of eﬀ ect of use of TKIs, 62 and 33 patients 
with preceding chronic myeloid leukaemia were 
diagnosed in 1980–99 and 2000–11, respectively, as 
having new solid cancers (adjusted HRs 2·97, 
95% CI 1·91–4·62 and 0·77, 0·36–1·62). The number of 
patients with preceding chronic myeloid leukaemia and 
new haematological cancers (n=15) was too small to 
allow this stratiﬁ cation. In the analysis of eﬀ ect of 
diagnostic misclassiﬁ cation on survival, the risk of 
death remained raised in patients with preceding 
myeloproliferative neoplasms: essential thrombo-
cythaemia, HR 1·61 (95% CI 1·29–2·02) without COPD 
and 1·49 (0·66–3·35) with COPD; polycythaemia vera, 
1·31 (1·17–1·48) without COPD and 2·51 (1·52–4·16) 
with COPD; and chronic myeloid leukaemia, 1·83 
(1·26–2·66) without COPD and 1·18 (0·30–4·74) 
with COPD.
Information on the immediate cause of death was 
retrieved from 889 patients with cancer and preceding 
myeloproliferative neoplasms and 3647 patients without 
preceding myeloproliferative neoplasms. Cause of 
death was not registered for 11 deceased patients. 5-year 
mortality and HRs for cardiovascular and thrombotic 
death were higher for patients with preceding essential 
thrombocythaemia or polycythaemia vera and a new 
solid cancer than for those without preceding essential 
thrombocythaemia or polycythaemia vera (appendix). 
For patients with preceding essential thrombocythaemia 
and a new solid cancer, increased 5-year mortality and 
HRs for death were also associated with infection or 
bleeding (appendix).
Figure 1: Survival in patients with and without preceding myeloproliferative 
neoplasms and with new solid cancers, stratiﬁ ed by extent of spread
(A) Patients with and without preceding ET. (B) Patients with and without 
preceding PV. (C) Patients with and without preceding CML. 
ET=essential thrombocythaemia. PV=polycythaemia vera. CML=chronic 
myeloid leukaemia.
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Discussion
In patients with preceding myeloproliferative neoplasms 
and localised solid cancer, 5-year survival was 
signiﬁ cantly lower than that in matched cancer patients 
without preceding myeloproliferative neoplasms. When 
adjusted for cancer stage and comorbidity score, 
preceding myeloproliferative neoplasms were associated 
with higher risk of mortality than in patients with new 
primary solid and haematological cancers and no 
history of myeloproliferative neoplasms. The eﬀ ect of 
previous chronic myeloid leukaemia on the prognosis of 
new cancers, however, was only evident for cancers 
diagnosed from 1980 to 1999, before this cancer was 
treated with TKIs.
The mechanism by which preceding myeloproliferative 
neoplasms aﬀ ect the prognosis of new primary cancers is 
unknown. Thrombocytosis is an almost universal ﬁ nding 
in untreated patients with myeloproliferative neoplasms, 
and platelets have been suggested to interact with tumour 
cells in solid cancers and promote growth, progression, 
and invasion.30 High platelet counts also have been 
suggested as a risk factor for cancer-associated venous 
thromboembolism,31,32 which in itself is associated with 
worsened prognosis.33 In our study, mortality due to 
cardiovascular or thrombotic disease was more frequent 
in patients with preceding myeloproliferative neoplasms 
than in those without and, therefore, these comorbidities 
might have contributed to worsened prognosis.
Because of the registry-based design of this study, we 
did not have access to detailed clinical data on severity of 
myeloproliferative neoplasms or treatment of these or 
new primary cancers. Since 2000, however, almost all 
patients with chronic myeloid leukaemia in Denmark 
have been treated with TKIs. After 2000, the outlook for 
patients with and without preceding chronic myeloid 
leukaemia who developed new solid cancers became 
similar. After 1 year of TKI therapy, most patients have 
minimum residual disease, whereas patients with other 
myeloproliferative neoplasms generally have persistent 
or progressive disease. With regard to the eﬀ ect of 
treatment on cancer prognosis, our ﬁ ndings support the 
clinical evidence that TKIs do not promote development 
of new cancers.12 The distinction between the eﬀ ect of 
other treatments for myeloproliferative neoplasms and 
the eﬀ ect of persistent disease is diﬃ  cult, but our 
ﬁ ndings underscore the need for eﬀ ective management 
of myeloproliferative neoplasms other than chronic 
myeloid leukaemia. For patients with preceding essential 
thrombocythaemia and polycythaemia vera, survival after 
being diagnosed as having a new primary cancer was 
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Figure 2: Survival in patients with and without preceding myeloproliferative 
neoplasms and with new solid cancers, stratiﬁ ed by comorbidity score
(A) Patients with and without preceding ET. (B) Patients with and without 
preceding PV. (C) Patients with and without preceding CML. ET=essential 
thrombocythaemia. PV=polycythaemia vera. CML=chronic myeloid leukaemia. 
CCI=Charlson Comorbidity Index score.
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signiﬁ cantly poorer than that previously reported in 
general patients with these cancers, even in those with 
early-stage cancers or no comorbidity.8
Generally, accuracy of coding diagnoses has been high 
in the DNPR.25 A possible study limitation of this study, 
however, is that diagnosis of myeloproliferative neoplasms 
was deﬁ ned by ICD codes, which might not be entirely 
accurate. When we stratiﬁ ed analyses according to COPD 
diagnosis, however, survival remained poorer among 
cancer patients with preceding myeloproliferative 
neoplasms but without COPD than among cancer patients 
without myeloproliferative neoplasms and COPD. 
Additionally, the eﬀ ect of myeloproliferative neoplasms on 
survival seemed to persist or even increase over time. 
Cancer-associated reactive thrombocytosis or poly-
cythaemia mistakenly diagnosed as essential thrombo-
cythaemia or polycythaemia vera seems unlikely to 
precede a subsequent solid cancer diagnosis by 5 years or 
longer. We noted similar results in patients with chronic 
myeloid leukaemia, for whom misclassiﬁ cation is unlikely 
because of the presence of the Philadelphia chromosome.
In our study non-melanoma skin cancer was seen more 
frequently than was expected from the general population 
cumulative incidence.26 Non-melanoma skin cancer 
occurring because of hydroxyurea has been reported in 
case reports.34 A limitation of our study, however, is low 
statistical precision in some subgroups when we stratiﬁ ed 
patients by extent of cancer spread and comorbidity.
Improvements in detection, treatment, and supportive 
care, have led to increasing numbers of patients being 
diagnosed as having multiple independent primary 
cancers, who now account for one in six patients with 
incident cancers.35 Although it seems self-evident that 
cancer patients with two neoplastic diseases would have 
poorer survival than patients with only one, outlook is 
generally good in patients with essential thrombo-
cythaemia or polycythaemia vera,5 and modern 
management of chronic myeloid leukaemia results in 
many patients achieving remission and long survival.6 
Hence, these high-prevalence cancer types are of interest 
to clinicians caring for patients with multiple primary 
cancers, one of which is a myeloproliferative neoplasm, 
to understand how prognosis might be aﬀ ected (panel).
ET HR (95% CI)* for death PV HR (95% CI)* for death CML HR (95% CI)* for death
<5 years ≥5 years <5 years ≥5 years <5 years ≥5 years
New solid cancer diagnosis
MPN vs no MPN 1·54 (1·16–2·04) 1·73 (1·23–2·44) 1·21 (1·01–1·44) 1·46 (1·26–1·70) 1·54 (0·95–2·49) 2·28 (1·33–3·91)
Cancer stage
Regional spread vs localised 1·92 (1·32–2·78) 1·72 (1·01–2·93) 2·03 (1·61–2·56) 1·72 (1·42–2·09) 2·10 (1·06–4·15) 2·04 (1·03–4·05)
Distant metastases vs localised 3·72 (2·52–5·49) 4·42 (2·52–7·72) 3·90 (3·07–4·95) 3·59 (2·93–4·40) 4·28 (2·22–8·27) 4·54 (2·02–10·20)
Unknown stage vs localised 1·72 (1·20–2·47) 2·00 (1·28–3·14) 1·85 (1·48–2·32) 1·64 (1·35–1·99) 1·60 (0·85–2·98) 1·34 (0·67–2·68)
CCI†
1–2 vs 0 1·47 (1·12–1·93) 1·64 (1·18–2·27) 1·68 (1·42–1·99) 1·26 (1·09–1·46) 1·02 (0·61–1·73) 1·38 (0·79–2·40)
≥3 vs 0 3·30 (1·87–5·82) 2·91 (1·47–5·77) 2·40 (1·65–3·49) 1·59 (1·19–2·12) 1·39 (0·47–4·12) 3·11 (0·98–9·86)
New haematological cancer diagnosis
MPN vs no MPN 1·28 (0·71–2·30) 2·26 (1·27–4·02) 1·41 (0·94–2·11) 1·40 (1·02–1·93) 6·04 (2·39–15·29) 3·90 (0·87–17·48)
CCI†
1–2 vs 0 1·33 (0·67–2·65) 1·85 (0·99–3·43) 1·25 (0·83–1·89) 1·25 (0·88–1·77) 0·85 (0·40–1·82) 2·67 (0·60–11·88)
≥3 vs 0 1·82 (0·60–5·56) 2·05 (0·50–8·40) 1·62 (0·80–3·29) 1·85 (0·89–3·82) 1·03 (0·33–3·18) ··
ET=essential thrombocythaemia. HR=hazard ratio. PV=polycythaemia vera. CML=chronic myeloid leukaemia. MPN=myeloproliferative neoplasm. CCI=Charlson Comorbidity 
Index score. *Compared with patients matched for age, sex, year of cancer diagnosis, and cancer type but with no preceding MPN; HRs are adjusted for MPN exposure, cancer 
stage (solid cancers only), and comorbidity. †Excludes cancers.
Table 4: Risk of death after developing a new solid or haematological cancer, by time since diagnosis of myeloproliferative neoplasms 
 Panel: Research in context
Systematic review
We searched PubMed with the search term 
“myeloproliferative neoplasm AND secondary cancer”. We 
identiﬁ ed 284 articles suitable for review but found no 
studies of the prognosis of secondary solid cancers in patients 
with myeloproliferative neoplasms.
Interpretation
Patients with essential thrombocythaemia, polycythaemia 
vera, or chronic myeloid leukaemia have a good outlook and, 
therefore, the prevalence of these cancer types is high. For 
clinicians caring for patients with multiple primary cancers, 
one of which is a myeloproliferative neoplasm, 
understanding of how prognosis might be aﬀ ected by 
myeloproliferative neoplasms is of interest. We found 
reduced survival in patients with preceding 
myeloproliferative neoplasms compared with that in cancer 
patients without preceding cancers of this type. Survival was 
also adversely aﬀ ected in patients with a preceding diagnosis 
of myeloproliferative neoplasm and a new cancer diagnosed 
at an early stage or without further comorbidity.
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